Catalyst
Slingshot members are tracking this event:
Gilead (GILD) Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GILD |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 24, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Bictegravir, Dolutegravir, Emtricitabine, Tenofovir Alafenamide, Hiv
